| Revenue growth | 36% YoY Q4 growth; full year FY26 remained largely flat. |
|---|---|
| Margins | 34.3% EBITDA margin in Q4; long-term sustainable range 26-28%. |
| Demand visibility | Low in Europe due to war; improving pilot-to-commercial transitions. |
| Management confidence | Balanced; emphasized deliberate groundwork over aggressive top-line expansion. |
Growth
Q4 revenue grew 36% YoY and 56% QoQ; EBITDA surged 69% sequentially due to better product mix.
Outlook
Block 7 commercial production starts Q2 FY27; CRAMS expected to drive visible outcomes throughout FY27.
Risks
Global geopolitical volatility and prolonged regulatory approvals in Europe/Japan delay commercialization of high-margin CRAMS projects.
Earnings Call filed with BSE, NSE: SGRL. Summary written with AI assistance from the document.
Shree Ganesh Remedies Ltd: key numbers
- Share price
- ₹672.35
- Market cap
- ₹863.1 Cr
- Revenue (annual)
- ₹109.3 Cr
- Net profit (annual)
- ₹17.76 Cr
- P/E (TTM)
- 55.9×Sector 50.4×
- Promoter holding
- 72.84%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shree Ganesh Remedies Ltd
All →Shree Ganesh Remedies Annual General Meeting
Shree Ganesh Remedies held its 31st Annual General Meeting on September 12, 2026. The meeting transacted ordinary and special business items, including director and auditor appointments.
Shree Ganesh Remedies Investor Presentation: Key Takeaways
Q1FY27 was challenging with Revenue/PAT declining 42%/68% YoY due to subdued European demand and termination of a distributor agreement. Management shifted focus to direct customer engagement and CRAMS projects.
Shree Ganesh Remedies Q1 FY27 Results: Net Profit ₹1.1 Cr, Down 67.6% YoY
Shree Ganesh Remedies Ltd reported revenue from operations of ₹14.4 Cr (-41.7% YoY) and net profit of ₹1.1 Cr (-67.6% YoY) for Q1 FY27.
- Key figure
- Net profit ₹1.1 Cr · -67.6% YoY
Shree Ganesh Remedies Earnings Call: Key Takeaways
Shree Ganesh Remedies reported Q4 FY26 revenue of INR 33.20 cr (up 36% YoY). Management characterized FY26 as a consolidation year, focusing on CRAMS pilot trials and capacity expansion.
Shree Ganesh Remedies Earnings Call: Key Takeaways
Shree Ganesh Remedies reported stagnant FY26 revenue of ₹109.3cr with a 23% PAT decline to ₹17.8cr. Focus remains on scaling CRAMS and specialty chemicals via expansion.
Shree Ganesh Remedies Q4 FY26 Results: Net Profit ₹6.3 Cr, Down 4.5% YoY
Shree Ganesh Remedies Ltd reported revenue from operations of ₹33.2 Cr (+36.1% YoY) and net profit of ₹6.3 Cr (-4.5% YoY) for Q4 FY26.
- Key figure
- Net profit ₹6.3 Cr · -4.5% YoY